Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: A secondary analysis of the randomized protocol RTOG 86-10

International Journal of Radiation Oncology Biology Physics

Volumn 54, Issue 5, 2002, Pages 1302-1310

  Shipley, William U ^a   Lu, J D ^b   Pilepich, Michael V ^c   Heydon, Kateri ^b   Roach III, Mack ^d   Wolkov, Harvey B ^e   Sause, William T ^f   Rubin, Philip ^g   Lawton, Colleen A ^h   Machtay, Mitchell ⁱ  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c ST JOSEPH MERCY HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Radiation Oncology Center   (United States)

^f LDS HOSPITAL   (United States)

^g UNIVERSITY OF ROCHESTER   (United States)

^h MEDICAL COLLEGE OF WISCONSIN   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

External beam radiotherapy; Neoadjuvant hormonal therapy; Prostate cancer; Salvage hormonal therapy

Indexed keywords

DIAGNOSIS; HORMONES; RADIOTHERAPY; SALVAGING; TUMORS;

HORMONAL THERAPY (HT);

ONCOLOGY;

ANTIANDROGEN; FLUTAMIDE; GONADORELIN DERIVATIVE; GOSERELIN;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; ARTICLE; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE TIME EFFECT RELATION; FOLLOW UP; HORMONAL REGULATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SALVAGE THERAPY; SEX HORMONE DETERMINATION; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FLUTAMIDE; GOSERELIN; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RECURRENCE; SALVAGE THERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 0036890728     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)03052-3     Document Type: Article

References (16)

1. Pilepich M.V., Krall J.M., Al-Sarraf M., et al. Androgen suppression with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma - A randomized comparative trial of the Radiation Therapy Oncology Group. Urology. 45:1995;616-623.
2. Bolla M., Gonzales D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 337:1997;295-300.
3. Pilepich M.V., Caplan R., Byhardt R.W., et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy Report of Radiation Therapy Oncology Group Protocol 85-31 . J Clin Oncol. 15:1997;1013-1021.
4. Hanks G.E., Lu J.D., Machtay M., et al. RTOG protocol 92-02 A phase III trial of the use of long-term androgen suppression following neoadjuvant hormonal cytoreduction in radiotherapy for locally advanced carcinoma of the prostate . 2000;. [Abstract]. Annual Proceedings of the American Society for Clinical Oncology, May.
5. Pilepich M.V., Winter K., Fu K.K., et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate. Proc Am Soc Clin Oncol (ASCO). 17:1998;308a.
6. Pilepich M.V., Winter K., Roach M., et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced prostate cancer. Int J Radiat Oncol Biol Phys. 50:2001;1243-1257.
7. Goldenberg S.L., Bruchovsky N. Androgen withdrawal therapy New prospectives in the treatment of prostate cancer . Raghvan D., Scher H., Leibel S. Principles and practice of genitourinary oncology. 1997;583-591 Lippincott-Raven, Philadelphia.
8. Bruchovsky N., Rennie P.S., Coldman A.J., et al. The effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res. 50:1990;. 7275-7222.
9. Scher H.I., Logothetis C.J. Regimens in androgen-independent prostatic cancer. Raghvan D., Scher H.I., Leibel S.A. Principles and practice of genitourinary oncology. 1997;599-604 Lippincott-Raven, Philadelphia.
10. Zelen M. The randomization and stratification of patients to clinical trials. J Chron Dis. 27:1974;365-375.
11. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
12. Kalbfleisch J.D., Prentice R.L. The statistical analysis of failure time data. 1980;John Wiley & Sons, New York.
13. Gray R.L. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 16:1988;1141-1154.
14. Cox J. Regression models and life tables. J Roy Stat Soc Series B. 34:1972;187-202.
15. Zietman A.L., Prince E.A., Nakfoor B.M., et al. Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate Experimental and clinical results . Urology. 49:1997;74-83.
16. Roach M. III, Lu J., Piliech M.V., et al. Predicting long-term survival and the need for hormonal therapy A meta-analysis of RTOG prostate cancer trials . Int J Radiat Oncol Biol Phys. 47:2000;617-627.